Navigation Links
ASTRO publishes supplement on protecting cancer patients by reducing radiation doses, side effects
Date:3/17/2010

The Quantitative Analysis of Normal Tissue Effects in the Clinic (QUANTEC) review has been published in the International Journal of Radiation Oncology*Biology*Physics, the official journal of the American Society for Radiation Oncology (ASTRO) to update recommendations for the safe irradiation of 16 organs. For each organ, the relationship between dose/volume and clinical outcome is reviewed. These reviews replace initial recommendations published in 1991.

When physicians began using radiation therapy to treat cancer, there was limited technology available to image a tumor and then target radiation specifically to it while limiting the dose to nearby healthy tissues. In the 1980s and 1990s, the field of imaging was revolutionized through the use of computed tomography-based diagnosis and radiation therapy treatment planning, allowing for treatments to be targeted more directly to the tumor and minimizing exposure to surrounding tissues.

No radiation treatment can be given while avoiding all nearby healthy tissue, but unlike cancer cells, normal tissue cells can repair themselves after receiving radiation. The QUANTEC review was published to help the radiation oncology treatment team decide which areas of healthy tissue surrounding a tumor can most safely receive radiation and to provide guidance for selecting doses/volumes to be treated.

The review also highlights areas in which there are gaps in knowledge and outlines future research in these areas.

"The information provided in the QUANTEC review is critical to providing cancer patients with the most effective radiation treatments to cure their cancer while minimizing side effects to normal tissue," Randall K. Ten Haken, Ph.D., one of the guest editors of the QUANTEC review and a professor at the University of Michigan Department of Radiation Oncology in Ann Arbor, Mich., said. "The field of radiation oncology is growing rapidly, and it's very important to know the limitations of the human body in receiving radiation; the QUANTEC review helps provide this information."

These reviews were produced through an extensive two-year project led by a QUANTEC steering committee comprising Dr. Ten Haken and fellow guest editor Lawrence B. Marks, M.D., a radiation oncologist at the University of North Carolina, Chapel Hill, as well as Sren M. Bentzen, Ph.D., D.Sc., University of Wisconsin in Madison, Wis., Louis S. Constine, M.D., University of Rochester in Rochester, N.Y., Joseph O. Deasy, Ph.D., Washington University in St. Louis, Avraham Eisbruch, M.D., University of Michigan in Ann Arbor, Mich., and Andrew Jackson, Ph.D., and Ellen D. Yorke, Ph.D., both from Memorial Sloan-Kettering Cancer Center in New York. Mary K. Martel, Ph.D., from M.D. Anderson Cancer Center in Houston served as an associate guest editor.

More than two dozen of the world's leading radiation oncologists, medical physicists and radiobiologists worked together on this extraordinary publication. The supplement can be found online at https://www.redjournal.org/issues.


'/>"/>

Contact: Beth Bukata
bethb@astro.org
703-839-7332
American Society for Radiation Oncology
Source:Eurekalert

Related medicine news :

1. Gastroenterology sets standards for CT colonography
2. ASTRO, Wellness Community South Bay Cities Join to Promote Cancer Survivorship
3. The First Incisionless Transoral Fundoplication for Treatment of Gastroesophageal Reflux is Performed in the U.S. at Ohio State University and Oregon Health & Science University Medical Centers
4. CYNACON/OCuSOFT (OCuSOFT, Inc.) Names Katherine M. Mastrota, M.S., O.D. to Medical Scientific Advisory Board
5. Frequently Asked Questions When Considering a Colorectal Cancer Screening Test, From the American College of Gastroenterology
6. Anti-depressant drugs can double risk of gastrointestinal bleeding
7. Endoscopic resection is a safe and effective treatment for gastrointestinal smooth muscle tumors
8. President of Uruguay to Speak at ASTRO Annual Meeting
9. Accuray Incorporated to Host Investor and Analyst Meeting at ASTRO 2007
10. Varian Medical Systems to Introduce RapidArc(TM) Radiotherapy Technology for Volumetric Arc Therapy at ASTRO 2007
11. Acute pancreatitis and cholangitis: a complication caused by a migrated gastrostomy tube
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... ... Sessions in Dallas that it will receive two significant new grants to support ... as PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is ... Road To Recovery® program to drive cancer patients to and from their cancer treatments. ... the highest quality of life and ongoing independence. Getting to and from medical ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The ... published in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital Partners, LLC ... by obtaining investment capital for emerging technology companies. SCP has delivered investment ... resulted in more than a million dollars of capital investment for five companies. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Today, MTI-GlobalStem, a ... cells and other difficult to transfect cells, announces its launch of the PluriQ™ ... Gene Editing System is a complete system for culturing and transfecting human ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Research and ... Global Market - Forecast to 2022" report to their ... treatment method for the patients with kidney failure, it replaces ... fluid from the patient,s blood and thus the treatment helps ... and chloride in balance. Increasing number of ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it ... (procalcitonin) assay as a dedicated testing solution for people ... Roche is the first IVD company in the U.S ... assessment and management. PCT is a sepsis-specific ... blood can aid clinicians in assessing the risk of ...
(Date:6/23/2016)... WAYNE, Pa. , June 23, 2016 ... provider, will launch its next generation clinical outcomes platform, Bracket ... DIA Meeting held on June 26 – 30, 2016 in ... 6.0, the first electronic Clinical Outcome Assessment product of its ... DIA Booth #715. Bracket eCOA 6.0 is a ...
Breaking Medicine Technology: